Additional file 2 of Inhibition of EZH2 by chidamide exerts antileukemia activity and increases chemosensitivity through Smo/Gli-1 pathway in acute myeloid leukemia
Additional file 2: Fig. S2. Chidamide doesn’t sensitize normal CD45+ and CD34+cells to adriamycin. Bone marrow samples from healthy donors were treated with chidamide (1.00 μmol/L), adriamycin (0.13 μmol/L) or both for 48 hours. Apoptosis in CD45+ and CD34+ cells was determined by flow cytometry. Ctrl, control; Chi, chidamide; ADM, adriamycin; Comb, combination.
Funding
Natural Science Foundation of Guangdong Province National Natural Science Foundation of China